Rajlaxmi Jain

Rajlaxmi Jain

Auto-generated profile, based on publicly available information

Rajlaxmi Jain

Indian Council of Medical Research-National Institute of Virology, Pune, India

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
Pragya Dhruv YadavPragya Dhruv Yadav
Pragya Dhruv Yadav
RERaches Ella
Raches Ella
SKSanjay Kumar
Sanjay Kumar
DPDilip R. Patil
Dilip R. Patil
SMSreelekshmy Mohandas
Sreelekshmy Mohandas
BBBalram Bhargava
Balram Bhargava
The COVID-19 pandemic is a global health crisis that poses a great challenge to the public health system of affected countries. Safe and effective vaccines are needed to overcome this crisis. Here, we develop and assess the protective efficacy and immunogenicity of an inactivated SARS-CoV-2 vaccine in rhesus macaques. Twenty macaques were divided into four groups of five animals each. One group was administered a placebo, while three groups were immunized with three different vaccine candidates of BBV152 at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 fourteen days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralizing antibody titers from 3rd-week post-immunization. Viral clearance was observed from bronchoalveolar lavage fluid, nasal swab, throat swab and lung tissues at 7 days post-infection in the vaccinated groups. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which exhibited interstitial pneumonia and localization of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry. This vaccine candidate BBV152 has completed Phase I/II (NCT04471519) clinical trials in India and is presently in phase III, data of this study substantiates the immunogenicity and protective efficacy of the vaccine candidates.

1 May 2020 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
GSGajanan Nagoji Sapkal
Gajanan Nagoji Sapkal
ASAnita Shete
Anita Shete
RJRajlaxmi Jain
Rajlaxmi Jain
Pragya Dhruv YadavPragya Dhruv Yadav
Pragya Dhruv Yadav
PSPrasad Sarkale
Prasad Sarkale
RGRaman R. Gangakhedkar
Raman R. Gangakhedkar
Background & objectives: Since the beginning of the year 2020, the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted humankind adversely in almost all spheres of life. The virus belongs to the genus Betacoronavirus of the family Coronaviridae. SARS-CoV-2 causes the disease known as coronavirus disease 2019 (COVID-19) with mild-to-severe respiratory illness. The currently available diagnostic tools for the diagnosis of COVID-19 are mainly based on molecular assays. Real-time reverse transcription-polymerase chain reaction is the only diagnostic method currently recommended by the World Health Organization for COVID-19. With the rapid spread of SARS-CoV-2, it is necessary to utilize other tests, which would determine the burden of the disease as well as the spread of the outbreak. Considering the need for the development of such a screening test, an attempt was made to develop and evaluate an IgG-based ELISA for COVID-19. Methods: A total of 513 blood samples (131 positive, 382 negative for SARS-CoV-2) were collected and tested by microneutralization test (MNT). Antigen stock of SARS-CoV-2 was prepared by propagating the virus in Vero CCL-81 cells. An IgG capture ELISA was developed for serological detection of anti-SARS-CoV-2 IgG in serum samples. The end point cut-off values were determined by using receiver operating characteristic (ROC) curve. Inter-assay variability was determined. Results: The developed ELISA was found to be 92.37 per cent sensitive, 97.9 per cent specific, robust and reproducible. The positive and negative predictive values were 94.44 and 98.14 per cent, respectively. Interpretation & conclusions: This indigenously developed IgG ELISA was found to be sensitive and specific for the detection of anti-SARS-CoV-2 IgG in human serum samples. This assay may be used for determining seroprevalence of SARS-CoV-2 in a population exposed to the virus.

1 May 2020 in Indian Journal of Medical Research
Verified
Journal Article
Open access
SMSreelekshmy Mohandas
Sreelekshmy Mohandas
RJRajlaxmi Jain
Rajlaxmi Jain
Pragya Dhruv YadavPragya Dhruv Yadav
Pragya Dhruv Yadav
ASAnita Shete-Aich
Anita Shete-Aich
PSPrasad Sarkale
Prasad Sarkale
RGRaman R. Gangakhedkar
Raman R. Gangakhedkar
Indian J Med Res, Official publication of Indian Council of Medical Research,India

16 October 2010 in Virus Genes
Verified
Journal Article
Open access
PDF file
CTC. Tosh
C. Tosh
HMH. V. Murugkar
H. V. Murugkar
SNS. Nagarajan
S. Nagarajan
STS. Tripathi
S. Tripathi
MKM. Katare
M. Katare
SDS. C. Dubey
S. C. Dubey
This study reports the genetic characterization of highly pathogenic avian influenza (HPAI) virus (subtype H5N1) isolated from poultry in West Bengal, India. We analyzed all the eight genome segments of two viruses isolated from chickens in January 2010 to understand their genetic relationship with other Indian H5N1 isolates and possible connection between different outbreaks. The hemagglutinin (HA) gene of the viruses showed multiple basic amino acids at the cleavage site, a marker for high virulence in chickens. Of greatest concern was that the viruses displayed amino acid substitution from serine-to-asparagine at position 31 of M2 ion channel protein suggesting emergence of amantadine-resistant mutants not previously reported in HPAI H5N1 outbreaks in India. Amino acid lysine at position 627 of the PB2 protein highlights the risk the viruses possess to mammals. In the phylogenetic trees, the viruses clustered within the lineage of avian isolates from India (2008–2009) and avian and human isolates from Bangladesh (2007–2009) in all the genes. Both these viruses were most closely related to the viruses from 2008 in West Bengal within the subclade 2.2.3 of H5N1 viruses.